Traci L. Bricker

TL;DR: Patients who die in the ICU following sepsis compared with patients who die of nonsepsis etiologies have biochemical, flow cytometric, and immunohistochemical findings consistent with immunosuppression, and targeted immune-enhancing therapy may be a valid approach in selected patients with sepsi.

TL;DR: In this article, rapid postmortem spleen and lung tissue harvest was performed at the bedsides of 40 patients who died in intensive care units (ICUs) of academic medical centers with active severe sepsis to characterize their immune status at the time of death (2009-2011).

TL;DR: In this paper, the authors report the in vitro and in vivo activity of a panel of monoclonal antibodies (mAbs) against SARS-CoV-2 variant viruses, which correspond to many mAb combinations in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron and Lilly.

TL;DR: The SARS-CoV-2 Assessment of Viral Evolution (SAVE) as mentioned in this paper was designed to provide a real-time risk assessment of SARS CoV2 variants that could potentially affect the transmission, virulence and resistance to infection-and vaccine-induced immunity.

TL;DR: These receptors are critical determinants of the duration of allergic airway inflammation and there is a temporally regulated expression of both the receptors and their ligands during the course of allergicAirway inflammation.